Innovating Works

BAYER AKTIENGESELLSCHAFT

Desconocido
Showing 1 to 20 of 87 results
VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado
BICEPS: Beyond neuroInflammation new Concepts to Elucidate the immune system s vital role in Parkinson s di... Decades of research into Parkinson's disease (PD) have fallen short in fully comprehending its mechanisms, leaving us without a cure. Curren...
2024-06-25 - 2028-10-31 | Financiado
INOVEC: a research and InNOvation Partnership for enhancing the surveillance and control of mosquito VECtors... BAYER AKTIENGESELLSCHAFT participó en un HORIZON EUROPE HORIZON-MSCA-2021-SE-01 Over the past 10 years, arboviral diseases, such as dengue, Zika, chikungunya and yellow fever, have (re)emerged with increasing prevalence...
2022-11-04 - 2026-12-31 | Financiado
BioMonitor4CAP: Advanced biodiversity monitoring for results-based and effective agricultural policy and transformat... BAYER AKTIENGESELLSCHAFT participó en un HORIZON EUROPE HORIZON-CL6-2022-BIODIV-01 Unsustainable agricultural practices are major drivers affecting habitat and species diversity in agricultural landscapes of the EU. Howeve...
2022-10-14 - 2026-11-30 | Financiado
BioDT: Biodiversity Digital Twin for Advanced Modelling, Simulation and Prediction Capabilities BAYER AKTIENGESELLSCHAFT participó en un HORIZON EUROPE HORIZON-INFRA-2021-TECH-01 With our planet facing an increasing reduction in biodiversity, it is of the utmost importance to understand the way climate, humans, pollut...
2022-05-31 - 2025-05-31 | Financiado
OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado
FACILITATE: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical eco... BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2020-23-two-stage FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process...
2021-10-11 - 2025-12-31 | Financiado
PERSIST-SEQ: Building a reproducible single cell experimental workflow to capture tumour cell persistence BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2020-20-two-stage It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by deve...
2021-06-28 - 2026-06-30 | Financiado
REsolution: Add medical genetic solutions to RESOLUTE REsolution BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2020-22-single-stage Solute carriers (SLCs) are the largest family of membrane transporters encoded in the human genome and their role in trafficking nutrients,...
2021-05-18 - 2023-12-31 | Financiado
ONTOX: Ontology driven and artificial intelligence based repeated dose toxicity testing of chemicals for ne... BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-SC1-BHC-2018-2020 The vision of the ONTOX consortium is to provide a functional and sustainable solution for advancing human risk assessment of chemicals with...
2021-01-29 - 2026-04-30 | Financiado
BIGPICTURE: Central Repository for Digital Pathology BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado
T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado
Gravitate-Health: Gravitate Health Empowering and Equipping Europeans with health information for Active Personal Hea... The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsiv...
2020-11-12 - 2025-10-31 | Financiado
ARDAT: Accelerating Research Development for Advanced Therapies BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado
SISAQOL-IMI: Establishing international standards in the analysis of patient reported outcomes and health related... BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2019-18-two-stage Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials. It is genera...
2020-11-09 - 2024-12-31 | Financiado
InPharma: A fully integrated animal free end to end modelling approach to oral drug product development BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-MSCA-ITN-2020 Oral drug products are preferred by hundreds of millions of patients in Europe. Yet, the challenges around formulating drugs for oral admini...
2020-09-07 - 2024-12-31 | Financiado
AIDD: Advanced machine learning for Innovative Drug Discovery BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-MSCA-ITN-2020 "The dramatic increase in using of Artificial Intelligence (AI) and machine learning methods in different fields of science becomes an essen...
2020-08-24 - 2025-03-31 | Financiado
ENLIGHT-TENplus: European Network Linking Informatics and Genomics of Helper T cells in Tissues BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-MSCA-ITN-2020 ENLIGHT-TEN+ is a European Network Linking Informatics and Genomics of Helper T cells in Tissues: A crucial missing link in our current rese...
2020-08-19 - 2025-02-28 | Financiado
AGePOP: Drug Absorption in Geriatric Patients and Older People a training network innovating drug developme... BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-MSCA-ITN-2020 The advanced age population (>65y) makes up ~20% of the total population in Europe, is the main carrier of chronic diseases and the major en...
2020-08-18 - 2024-12-31 | Financiado
CARE: Corona Accelerated R D in Europe BAYER AKTIENGESELLSCHAFT participó en un H2020 H2020-JTI-IMI2-2020-21-single-stage The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in thi...
2020-08-07 - 2025-03-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.